319 related articles for article (PubMed ID: 30284761)
1. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
Bielsky AR; Fuhr PG; Parsons JA; Yaster M
Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
[TBL] [Abstract][Full Text] [Related]
2. Anesthetic management of pediatric patients undergoing intrathecal nusinersen administration for treatment of spinal muscular atrophy: A single-center experience.
Brollier LD; Matuszczak M; Marri T; Carbajal JG; Moorman AT; Sorial EM; Jain R
Paediatr Anaesth; 2021 Feb; 31(2):160-166. PubMed ID: 32623818
[TBL] [Abstract][Full Text] [Related]
3. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
5. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
6. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1.
Pechmann A; Langer T; Wider S; Kirschner J
Eur J Paediatr Neurol; 2018 Jan; 22(1):122-127. PubMed ID: 29208343
[TBL] [Abstract][Full Text] [Related]
7. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
8. Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen.
Salerno A; Picconi E; Genovese O; Piastra M; Pulitanò SM; Tosi F; Mancino A; Pane M; De Sanctis R; Carlini D; Mercuri EM; Conti G
Paediatr Anaesth; 2023 Apr; 33(4):282-290. PubMed ID: 36636888
[TBL] [Abstract][Full Text] [Related]
9. The Complex Spine in Children with Spinal Muscular Atrophy: The Transforaminal Approach-A Transformative Technique.
Towbin R; Schaefer C; Kaye R; Abruzzo T; Aria DJ
AJNR Am J Neuroradiol; 2019 Aug; 40(8):1422-1426. PubMed ID: 31296522
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients.
Wurster CD; Winter B; Wollinsky K; Ludolph AC; Uzelac Z; Witzel S; Schocke M; Schneider R; Kocak T
J Neurol; 2019 Jan; 266(1):183-194. PubMed ID: 30460449
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
Acsadi G; Crawford TO; Müller-Felber W; Shieh PB; Richardson R; Natarajan N; Castro D; Ramirez-Schrempp D; Gambino G; Sun P; Farwell W
Muscle Nerve; 2021 May; 63(5):668-677. PubMed ID: 33501671
[TBL] [Abstract][Full Text] [Related]
12. Procedural sedation for paediatric patients with spinal muscular atrophy undergoing intrathecal treatment.
Sever F; Özmert S; Arıbaş Öz N
Br J Clin Pharmacol; 2023 Aug; 89(8):2465-2471. PubMed ID: 36932845
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
[TBL] [Abstract][Full Text] [Related]
15. Anesthesia and perioperative medical management of children with spinal muscular atrophy.
Graham RJ; Athiraman U; Laubach AE; Sethna NF
Paediatr Anaesth; 2009 Nov; 19(11):1054-63. PubMed ID: 19558636
[TBL] [Abstract][Full Text] [Related]
16. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
[TBL] [Abstract][Full Text] [Related]
17. Computed-tomography-guided transforaminal intrathecal nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations.
Spiliopoulos S; Reppas L; Zompola C; Palaiodimou L; Papadopoulou M; Filippiadis D; Palialexis K; Ploussi A; Efstathopoulos E; Tsivgoulis G; Brountzos E
Eur J Neurol; 2020 Jul; 27(7):1343-1349. PubMed ID: 32250518
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
19. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
20. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
